Fujisawa Pharmaceutical Company, Ltd.

Nitto Electric Industrial Co., Ltd.

Nitto-Denko Corporation

Astellas Pharma Gmbh

The Hollenniun Laboratories

Meiryo Technica Corporation, Ltd.

Susumu Satoh

Hiroyuki Arakawa

Ikuo Ueda

Masahiko Morita

Mayako Yamazaki

Masaaki Matsuo

Takao Isogai

Tetsuo Nishikawa

Toshio Ota

Yuri Hio

Yoko Abe

Takao Watanabe

Jorge Heller

Mitsuhiko Hori

Mineo Niwa

Tetsuo Omata

Hiroki Ono

Wilfred A Skinner

Shintaro Nishimura

Tadashi Kitaguchi

Kenichiro Saito

Mitsuru Tamada

Sousuke Miyoshi

Masafumi Koide

Ichiro Kobayashi

Yumiko Takakura

Yoshiaki Itoh

Naoko Yamanaka

Yasuhiro Kita

Takao Yamazaki

Yoko Tsuda

Hiroshi Marusawa

Yoshimasa Saitoh

Chihiro Kusunoki

Yoshitaka Sakamoto

Juichiro Nakashima

Akiko Suzuki

The present invention identified OVARC1000473 (SEQ ID NO: 1) and NT2RM1000377 (SEQ ID NO: 3) as clones showing suppression of CREB activation by forskolin, and provides evaluation methods using these genes, and/or proteins encoded by these genes. Furthermore, these proteins were found to enhance cell damage. Compounds that can be screened based on the evaluation methods of this invention are useful as agents for inhibiting the CREB dephosphorylation reaction, agents for suppressing enhancement of cell damage, and preventive and therapeutic agents for memory disorders and/or neurodegenerative disorders.

Methods of evaluating phosphatase inhibitors

A molecule introducing apparatus is provided with a power supply circuitfor supplying power, a step-up transformerwhich is supplied with power from the power supply circuitand which outputs a high voltage, a switching transistorthat blocks off and allows the supply of power from the power supply circuitto the step-up transformerand which generates an instantaneous high voltage, and a pair of electrode probesfor applying the instantaneous high voltage generated at the step-up transformerto a predetermined region in a body. The molecule introducing apparatus oscillates DNA arranged outside a cell by the instantaneous high voltage so as to introduce the DNA into the cell.

Molecule transferring device, auxiliary for molecule transferring device, and molecule transferring method

The present invention provides: proteins suppressing or promoting the aggregation or deposition of amyloid-&#x3b2; protein; polynucleotides encoding the proteins; a method for screening a compound suppressing or promoting the aggregation or deposition of amyloid-&#x3b2; protein; and therapeutic agents for treating or preventing Alzheimer's diseases comprising a compound that regulates the activity of a protein suppressing or promoting the aggregation or deposition of amyloid-&#x3b2; protein.

Amyloid-&#x3b2; protein aggregation-regulating factors

Amyloid &#x3b2; protein agglutination-controlling factor

A medical composition for external use comprising a proline ester represented by formula (I): ##STR1## wherein R.sub.1 and R.sub.2 are as defined in the specification, or a prolinol ester represented by formula (II): ##STR2## wherein R.sub.3 and R.sub.4 are as defined in the specification. The composition enhances percutaneous penetration absorption of an active ingredient to be combined therewith.

Medical composition for percutaneous administration

IGF-I fused with a protective peptide, in which the protective peptide is a protein peptide and is used for the protection of IGF-I from degradation by protease in cells of E. coli is disclosed. Also disclosed are genes coding for the fused IGF-I's, plasmids containing the genes, and E. coli microorganisms transformed with the plasmids.

IGF-I fusion proteins; protection of IGF-I from degradation by host

A composition for percutaneous drug administration which contains a compound of the general formula ##STR1## wherein R.sub.1 is a hydrogen atom or an alkyl group and R.sub.2 is a residue of aliphatic hydrocarbon. The composition is capable of promoting percutaneous drug absorption.

Method of promoting percutaneous drug absorption with 2-pyrrolidin-2-one

A composition for percutaneous administration containing a nicotinic ester represented by formula (I) ##STR1## or an isonicotinic ester represented by formula (II) ##STR2## wherein R and R' each represents an alkyl group having 5 or more carbon atoms, with or without a specific polar compound. The composition improves percutaneous absorption of an active ingredient.

Composition for percutaneous administration

A method of percutaneously administering a physiologically active agent which comprises applying to the skin of a mammal a physiologically active agent in a carrier system which comprises at least one adjuvant and at least one solvent. The adjuvant can be selected from aliphatic hydrocarbons, halogen substituted aliphatic hydrocarbons, alcohol esters of aliphatic carboxylic acids, mono- or di-ethers, ketones, or mixtures thereof. The solvent can be selected from thioglycerols, lactic acid and esters thereof, cyclic ureas, compounds represented by the general formula R.sub.1 R.sub.2 NCONR.sub.3 R.sub.4, pyrrolidone-type compounds, amides, lactones or mixtures thereof.

Method for percutaneously administering physiologically active agents

A composition capable of promoting the skin permation or percutaneous absorption of a medicament, which comprises at least one adjuvant selected from the group consisting of a saturated hydrocarbon containing 5 to 20 carbon atoms which may be substituted by halogen, an alcohol ester of aliphatic carboxylic acid containing 12 to 18 carbon atoms, an ether, a dimethylpolysiloxane having a viscosity at 25.degree. C. of not more than 6 centistokes and a cyclic polydimethylsiloxane having a viscosity at 25.degree. C. of not more than 6 centistokes, and an imidazolidinone derivative represented by the general formula: ##STR1## wherein R.sub.1 and R.sub.2 each are a lower alkyl group; and pharmaceutical composition for external medication.

Base composition for medicament and pharmaceutical composition for

The invention is directed to compounds of the formula ##STR1## wherein R.sub.a.sup.1 is phenyl,

Lower alkanoic acid derivatives of 2-oxo-benzoxazolines and aldose

A pharmaceutical composition comprising certain benzothiazoline alkanoic acid derivatives for the prevention and treatment of various diabetic complications, said derivatives being inhibitors of aldose reductase.

Benzothiazol-2-one-3-alkanoic acids and esters and aldose reductase

Growing community of inventors

Osaka, Japan

Susumu Satoh